Advanced search
Publication Cover
Future Oncology Volume 18, 2022 - Issue 17
Submit an article Journal homepage
1,246
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors

Yi-Long Wu1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaORCID Iconhttps://orcid.org/0000-0002-3611-0258View further author information
ORCID Icon,
Ying Cheng2 Department of Medical Oncology,Jilin Cancer Hospital,Changchun, Jilin, 130012, ChinaView further author information
,
Huajun Chen1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaView further author information
,
Haiyan Tu1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaORCID Iconhttps://orcid.org/0000-0001-7125-9878View further author information
ORCID Icon,
Chongrui Xu1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaORCID Iconhttps://orcid.org/0000-0002-3474-2809View further author information
ORCID Icon,
Zhen Wang1 Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,& Guangdong Academy of Medical Sciences,Guangzhou, 510080, ChinaView further author information
,
Ying Liu2 Department of Medical Oncology,Jilin Cancer Hospital,Changchun, Jilin, 130012, ChinaView further author information
,
Ying Xin2 Department of Medical Oncology,Jilin Cancer Hospital,Changchun, Jilin, 130012, ChinaView further author information
,
Haizhou Lou3 Department of Medical Oncology, Sir Run Shaw Hospital,Zhejiang University,Hangzhou, Zhejiang, 310016, ChinaView further author information
,
Wei Wang3 Department of Medical Oncology, Sir Run Shaw Hospital,Zhejiang University,Hangzhou, Zhejiang, 310016, ChinaView further author information
,
Kevin Chin4 EMD Serono Research & Development Institute, Inc.,Billerica,MA 01821, USA, an affiliate of Merck KGaAView further author information
,
Dandan Li5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
,
Di Zhao5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
,
Yanfei Gao5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
,
Wenping Xu5 Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaAView further author information
&
Hongming Pan3 Department of Medical Oncology, Sir Run Shaw Hospital,Zhejiang University,Hangzhou, Zhejiang, 310016, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 2053-2062 | Received 17 Oct 2021, Accepted 09 Mar 2022, Published online: 31 Mar 2022

References

  • D'Angelo SP , BhatiaS, BrohlASet al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase II JAVELIN Merkel 200 trial. J. Immunother. Cancer8(1), e000674 (2020).
  • Powles T , ParkSH, VoogEet al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med.383(13), 1218–1230 (2020).
  • Apolo AB , EllertonJA, InfanteJRet al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN solid tumor study: 2-year updated efficacy and safety analysis. J. Immunother. Cancer8(2), e001246 (2020).
  • Barlesi F , VansteenkisteJ, SpigelDet al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase III study. Lancet Oncol.19(11), 1468–1479 (2018).
  • Keilholz U , MehnertJM, BauerSet al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer7(1), 12 (2019).
  • Hassan R , ThomasA, NemunaitisJJet al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor trial. JAMA Oncol.5(3), 351–357 (2019).
  • Kelly K , InfanteJR, TaylorMHet al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase I JAVELIN Solid Tumor and phase II JAVELIN Merkel 200 clinical trials. Cancer124(9), 2010–2017 (2018).
  • D'Angelo SP , RussellJ, LebbeCet al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol.4(9), e180077 (2018).
  • Choueiri TK , MotzerRJ, RiniBIet al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol.31(8), 1030–1039 (2020).
  • Bavencio (avelumab) . Prescribing information. EMD Serono (2020). www.bavencio.com/content/dam/web/health-care/biopharma/web/Bavencio/us/redesign/hcp/bavencio-hcp-home/bavencio-pi.pdf
  • Bavencio (avelumab) . Summary of product characteristics. Merck KGaA, Darmstadt, Germany (2020). www.ema.europa.eu/documents/product-information/bavencio-epar-product-information_en.pdf
  • Rajman I , HiranoM, HonmaW, ZhaoS. New paradigm for expediting drug development in Asia. Drug Discov. Today25(3), 491–496 (2020).
  • Peng L , QinBD, XiaoKet al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology9(1), 1781333 (2020).
  • Ma Y , LinQ, YangYet al. Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients. Ann. Transl. Med.8(5), 236 (2020).
  • Doi T , IwasaS, MuroKet al. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer22(4), 817–827 (2019).
  • Heery CR , O'Sullivan-CoyneG, MadanRAet al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol.18(5), 587–598 (2017).
  • Enrico D , PaciA, ChaputN, KaramouzaE, BesseB. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation?Clin. Cancer Res.26(4), 787–792 (2020).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.